Table 1 Clinicopathological features of BC patients from TCGA dataset
Clinicopathological features | Low expression of VDAC1 | High expression of VDAC1 |
|---|---|---|
n | 532 | 533 |
Age, n (%) | ||
 ≤60 | 297 (27.9%) | 291 (27.3%) |
 >60 | 235 (22.1%) | 242 (22.7%) |
T stage, n (%) | ||
 T1 | 147 (13.8%) | 128 (12.1%) |
 T2 | 294 (27.7%) | 321 (30.2%) |
 T3 | 68 (6.4%) | 69 (6.5%) |
 T4 | 23 (2.2%) | 12 (1.1%) |
N stage, n (%) | ||
 N0 | 258 (24.7%) | 249 (23.8%) |
 N1 | 180 (17.2%) | 169 (16.2%) |
 N2 | 52 (5%) | 64 (6.1%) |
 N3 | 34 (3.3%) | 40 (3.8%) |
M stage, n (%) | ||
 M0 | 431 (47.4%) | 458 (50.4%) |
 M1 | 9 (1%) | 11 (1.2%) |
Pathologic stage, n (%) | ||
 Stage I | 94 (9%) | 86 (8.3%) |
 Stage II | 308 (29.6%) | 298 (28.6%) |
 Stage III | 111 (10.7%) | 127 (12.2%) |
 Stage IV | 9 (0.9%) | 9 (0.9%) |
ER status, n (%) | ||
 Negative | 138 (13.6%) | 99 (9.7%) |
 Positive | 375 (36.9%) | 403 (39.6%) |
PR status, n (%) | ||
 Negative | 187 (18.4%) | 151 (14.9%) |
 Positive | 323 (31.8%) | 351 (34.5%) |
HER2 status, n (%) | ||
 Negative | 293 (40.9%) | 255 (35.6%) |
 Positive | 62 (8.6%) | 95 (13.2%) |